European Market for Bone Morphogenic Proteins

Growing at an impressive compound annual growth rate of 61%, the market for bone morphogenic proteins (BMPs) is set to reach U.S.$16.3 million in 2010, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), the international consulting firm. BMPs are a new, innovative class of natural growth factors that can be used either as adjuncts or as alternatives to current surgical procedures for the fusion of spinal vertebrae.

The increased incidence of degenerative diseases of the lower back is expected to be a key growth driver in the BMP market. As more people opt for surgical procedures to alleviate back pain caused by degenerative diseases, demand for spinal fusion products is set to soar. In clinical studies on humans, BMPs appeared to improve fusion rates compared with the autograph "gold standard” bone-grafting techniques. BMPs offer the prospect of substantially reducing patient mortality associated with autogenous bone grafting.

While BMPs offer significant clinical advantages over autologous bone and bone graft materials, high costs could constrain sales. Biocompatibility and safety concerns over excessive bone growth could further curb market expansion, while dosage and carrier matrix issues are likely to remain major challenges. Although the first products to be launched in the recombinant BMP area consist of a single BMP, the most effective treatment is likely to comprise a cocktail of multiple BMPs.

"There consequently exists an opportunity for researchers and developers to collaborate on the development and commercialization of one of these cocktail growth-factor products,” noted Tanya Pullen, Frost & Sullivan program manager.




Related Links:
Frost & Sullivan